We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Therapy Technique Cures Cystic Fibrosis in Culture Model

By LabMedica International staff writers
Posted on 31 Jul 2009
A gene therapy technique based on a parainfluenza virus vector was used to successfully cure an in vitro model of cystic fibrosis.

Cystic fibrosis (CF) lung disease results from reduced airway surface hydration leading to decreased mucus clearance that precipitates bacterial infection and progressive obstructive lung disease. CF is a genetic disease, and the mutant protein is a chloride ion channel (CFTR) that normally regulates ion and fluid transport on the airway surface.

Investigators at the University of North Carolina (Chapel Hill, USA) reasoned that the most appropriate means for delivering a gene to lung tissue was a virus that specialized in invading the lungs. They created an in vitro model of CF by growing cultures of ciliated surface airway epithelium (CF HAE) cells obtained from a CF patient. The cultures were then treated with parainfluenza virus that had been genetically engineered to carry the normal CFTR gene.

Results published in the July 21, 2009, online edition of the journal PLoS Biology revealed that the vector delivered CFTR to more than 60% of airway surface epithelial cells, and the expression of CFTR protein in the CF HAE cells was approximately 100-fold higher than endogenous levels found in normal HAE cells.

By titering the amount of CFTR gene in the vector, the investigators were able to determine that uptake of the gene by 25% of the cells was sufficient to restore normal function to the entire culture.

"We discovered that if you take a virus that has evolved to infect the human airways, and you engineer a normal CFTR gene into it, you can use this virus to correct all of the hallmark CF features in the model system that we used,” said senior author Dr. Raymond J. Pickles, associate professor of microbiology and immunology at the University of North Carolina. "This is the first demonstration in which we have been able to execute delivery in an efficient manner. When you consider that in past gene therapy studies, the targeting efficiency has been somewhere around 0.1% of cells, you can see this is a giant leap forward.”

"We have not generated a vector that we can go out and give to patients now,” said Dr. Pickles, "but these studies continue to convince us that a gene replacement therapy for CF patients will some day be available in the future.”

Related Links:
University of North Carolina


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Connectivity Solution
EKF Link

Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more